E. Terruzzi

发表

Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL).

T. Barbui, A. Bosi, A. Gallamini, 2009, Blood.

Randomized trial comparing standard vs sequential high-dose chemotherapy for inducing early CR in adult AML.

B. Falini, A. Bosi, A. Cortelezzi, 2019, Blood advances.

Poster Sessions I and II , Interdisciplinary Workshop, Satelite Symposia I-IV

T. Chisesi, A. Rambaldi, R. Bassan, 2004, Annals of Hematology.

Title: Achieving a Molecular Remission before Allogeneic Stem Cell Transplantation in Adult Patients with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia: Impact on Relapse and Long Term Outcome

Margherita, Arianna, F. Mannelli, 2016 .

Chemotherapy-phased imatinib pulses improve long-term outcome of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: Northern Italy Leukemia Group protocol 09/00.

A. Levis, F. Mannelli, G. Rossi, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long‐term follow‐up of patients with intermediate or high‐grade non‐Hodgkin lymphoma treated with a combination of cyclophosphamide, epirubicin, vincristine, and prednisone

E. Pogliani, E. Terruzzi, F. Rossini, 2004, Cancer.

Achieving Molecular Remission before Allogeneic Stem Cell Transplantation in Adult Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Impact on Relapse and Long-Term Outcome.

F. Mannelli, A. Cortelezzi, F. Ciceri, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Good Outcome for Very High Risk Adult B-cell Acute Lymphoblastic Leukaemia Carrying Genetic Abnormalities t(4;11)(q21;q23) or t(9;22)(q34;q11), if Promptly Submitted to Allogeneic Transplantation, after Obtaining a Good Molecular Remission

M. Fumagalli, G. Cazzaniga, P. Pioltelli, 2015, Mediterranean journal of hematology and infectious diseases.

Peg-filgrastim versus filgrastim after autologous stem cell tranplantation: case-control study in patients with multiple myeloma and review of the literature.

F. Morabito, P. Musto, M. Valvano, 2007, Leukemia research.

Management of poor peripheral blood stem cell mobilization: incidence, predictive factors, alternative strategies and outcome. A retrospective analysis on 2177 patients from three major Italian institutions.

F. Ravagnani, P. Pioltelli, P. Perseghin, 2009, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

Cytomegalovirus infection after autologous stem cell transplantation: incidence and outcome in a group of patients undergoing a surveillance program

M. Fumagalli, E. Pogliani, F. Morini, 2005, Transplant infectious disease : an official journal of the Transplantation Society.

A fatal case of TEMPI syndrome, refractory to proteasome inhibitors and autologous stem cell transplantation.

C. Gambacorti-Passerini, R. Piazza, P. Perfetti, 2020, Leukemia research.

Pentraxin 3 plasma levels at graft-versus-host disease onset predict disease severity and response to therapy in children given haematopoietic stem cell transplantation

C. Garlanda, A. Mantovani, M. Valsecchi, 2016, Oncotarget.

GITMO REGISTRY STUDY ON ALLOGENEIC TRANSPLANTATION IN PATIENTS AGED OVER 60 FROM 2000 TO 2017. IMPROVEMENTS AND CRITICISMS

P. Mazza, V. Pavone, P. Chiusolo, 2021, Transplantation and Cellular Therapy.

Allogeneic hemopoietic stem cell transplants in patients with acute myeloid leukemia (AML) prepared with Busulfan Fludarabine (BUFLU) or Thiotepa Busulfan Fludarabine (TBF): a retrospective study.

P. Chiusolo, A. Bacigalupo, E. Angelucci, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: an open-label, multicentre, randomised, phase 3 trial.

P. Chiusolo, A. Nagler, A. Bosi, 2015, The Lancet. Oncology.

Severe, reversible nelarabine‐induced neuropathy and myelopathy

G. Cavaletti, P. Alberti, P. Pioltelli, 2016, Journal of the peripheral nervous system : JPNS.

Acute GVHD prophylaxis plus ATLG after myeloablative allogeneic haemopoietic peripheral blood stem-cell transplantation from HLA-identical siblings in patients with acute myeloid leukaemia in remission: final results of quality of life and long-term outcome analysis of a phase 3 randomised study.

N. Kröger, J. Sierra, A. Nagler, 2019, The Lancet. Haematology.

Antilymphocyte Globulin for Prevention of Chronic Graft-versus-Host Disease.

Giuseppe Milone, Stefano Guidi, Arnon Nagler, 2016, The New England journal of medicine.

Gene Abnormalities in Transplant Associated-Thrombotic Microangiopathy: Comparison between Recipient and Donor's DNA.

G. Ardissino, D. Consonni, L. Facchini, 2021, Thrombosis and haemostasis.

Successful treatment with T-depleted autologous peripheral blood stem cell transplantation of refractory chronic autoimmune thrombocytopenic purpura.

P. Pioltelli, P. Perseghin, M. Dassi, 2007, Haematologica.

Allogeneic Stem Cell Transplantation for Relapsed/Refractory B Cell Lymphomas: Results of a Multicenter Phase II Prospective Trial including Rituximab in the Reduced-Intensity Conditioning Regimen.

R. Miceli, A. Bosi, B. Sarina, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Factors predicting outcome after allogeneic transplant in refractory acute myeloid leukemia: a retrospective analysis of Gruppo Italiano Trapianto di Midollo Osseo (GITMO)

P. Chiusolo, A. Santoro, A. Bosi, 2017, Bone Marrow Transplantation.

Busulfan or Treosulfan Conditioning Platform for Allogeneic Stem Cell Transplantation in Patients Aged >60 Y With Acute Myeloid Leukemia/Myelodysplastic Syndrome: A Subanalysis of the GITMO AlloEld Study

P. Mazza, V. Pavone, P. Chiusolo, 2023, Transplantation direct.

Clinical significance of chromatin-spliceosome acute myeloid leukemia: a report from the Northern Italy Leukemia Group (NILG) randomized trial 02/06

B. Falini, F. Mannelli, A. Cortelezzi, 2020, Haematologica.

A randomized clinical trial of ceftriaxone and amikacin versus piperacillin tazobactam and amikacin in febrile patients with hematological neoplasia and severe neutropenia

A. Larocca, E. Pogliani, E. Terruzzi, 2005, Supportive Care in Cancer.

Gastroduodenal lesions in polycythaemia vera: frequency and role of Helicobacter pylori

C. Abbiati, R. de Franchis, G. Bertinieri, 2002, British journal of haematology.

A Single-Arm, Open-Label Phase 1 Study of Itacitinib (ITA) with Calcineurin Inhibitor (CNI)-Based Interventions for Prophylaxis of Graft-Versus-Host Disease (GVHD; GRAVITAS-119)

M. Arbushites, M. Perales, P. Chevallier, 2020 .